Peppa Opdivo has shown an advantage in esophageal cancer

's
nivolumab shows signs of promising in a Phase III clinical trial of CheckMate-577 involving patients with
who previously under received new assisted chemical radiotherapy (CRT) and tumor excision
esophageal cancer or gastroesophageal junction (GEJ) cancer.The results, presented at a virtual meeting of the European Society of Medical Oncology (ESMO) in 2020, showed that patients treated with Opdivo (nivolumab) had an average disease-free survival rate of twice as many patients as those treated with a placebo after surgery.The medium treatment time was 10.1 months for patients in the Opdivo group and 9 months in the placebo group.
point inhibitors
good tolerance and acceptable safety compared to placebos.“ These results make esophageal and gastroesophageal cancer the second type of cancer after melanoma, where Opdivo has shown benefits in adpothesic therapy, suggesting that Opdivo may be the new standard of treatment for these patients. Ian waxman
head of gastrointestinal cancer at
," said Ian Waxman,
head of
.He added: "This advance demonstrates our commitment to evaluating our therapies at an early stage of the disease, where we may have a greater impact on preventing disease recurrence and improving patient prognostication."approved in this case,
's Best Of America
intends to discuss the results of the CheckMate-577 study with global health authorities over the next few months. (cyy123.com)original source: Bristol Myers Squibb's Opdivo show benefit in oesophageal cancers